Dikoma Shungu has been pivotal
Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese
The goal is to provide a factual and rigorous resource enabling everyone to form an informed opinion about this promising peptide
Your prescribing provider needs to know about all medications you take so they can adjust your GLP-1 dose appropriately and monitor you for unexpected changes in appetite, mood, or digestive symptoms during the first few weeks of treatment
Integrated network pharmacology and gut microbiota analysis to explore the mechanism of Sijunzi decoction involved in alleviating airway inflammation in a mouse model of asthma
, stable in human gastric juice more than 24 hours, and use without carrier (otherwise, peptide + carrier(s) -complex bears considerable methodological/activity dilemmas), prominent antiulcer effect, and a safe application in inflammatory bowel disease patients with improved wound/intestinal anastomosis healing, adhesion prevention, collagen deposition, and anastomotic strength, along with prominent effect in cuprizone rats ( i.e
